Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication

• Published in: Blood cancer journal (New York) Vol. 11; no. 2; pp. 39 - 14
• Main Authors: Lu, Pin, Wang, Shengchun, Franzen, Carrie A., Venkataraman, Girish, McClure, Rebecca, Li, Lei, Wu, Wenjun, Niu, Nifang, Sukhanova, Madina, Pei, Jianming, Baldwin, Donald A., Nejati, Reza, Wasik, Mariusz A., Khan, Nadia, Tu, Yifan, Gao, Juehua, Chen, Yihua, Ma, Shuo, Larson, Richard A., Wang, Y. Lynn
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 18-02-2021; Springer Nature B.V; Nature Publishing Group
• Subjects: 13; 13/2; 13/21; 13/31; 692/308/575; 692/699/1541; 82; 96/1; Apoptosis; Behavior; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cancer therapies; Cell growth; Clinical trials; Drug testing; Drugs; Fibroblasts; Flow cytometry; Hematology; Kinases; Laboratories; Leukemia; Oncology; Patients; Targeted cancer therapy
• ISSN: 2044-5385; 2044-5385
• DOI: 10.1038/s41408-021-00429-z

Ibrutinib inhibits Bruton tyrosine kinase while venetoclax is a specific inhibitor of the anti-apoptotic protein BCL2. Both drugs are highly effective as monotherapy against chronic lymphocytic leukemia (CLL), and clinical trials using the combination therapy have produced remarkable results in terms of rate of complete remission and frequency of undetectable minimal residual disease. However, the laboratory rationale behind the success of the drug combination is still lacking. A better understanding of how these two drugs synergize would eventually help develop other rational combination strategies. Using an ex vivo model that promotes CLL proliferation, we show that modeled ibrutinib proliferative responses, but not viability responses, correlate well with patients’ actual clinical responses. Importantly, we demonstrate for the first time that ibrutinib and venetoclax act on distinct CLL subpopulations that have different proliferative capacities. While the dividing subpopulation of CLL responds to ibrutinib, the resting subpopulation preferentially responds to venetoclax. The combination of these targeted therapies effectively reduced both the resting and dividing subpopulations in most cases. Our laboratory findings help explain several clinical observations and contribute to the understanding of tumor dynamics. Additionally, our proliferation model may be used to identify novel drug combinations with the potential of eradicating residual disease.